$99.700
-0.289 (-0.29%)Zum Schluss
LNTH-News
LNTH-Events
Lantheus Secures Transitional Payment Status for PYLARIFY TruVu
Lantheus Holdings announced that the Centers for Medicare & Medicaid Services, CMS, has granted Transitional Pass-Through, TPT, payment status for PYLARIFY TruVu injection, effective October 1, 2026. The designation enables separate reimbursement for PYLARIFY TruVu in the hospital outpatient setting and is intended to support access to innovative diagnostic radiopharmaceuticals for Medicare beneficiaries.
Lantheus Doses First Patient in LNTH-2401 Trial
Lantheus announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluating LNTH-2401. LNTH-2401 is an investigational gallium-68-labeled positron emission tomography imaging agent that targets the gastrin-releasing peptide receptor, a biomarker that is highly expressed in many prostate cancers.
Lantheus Receives FDA Approval for Bravnesta
Lantheus announced that the U.S. Food and Drug Administration, FDA, has granted final approval for Bravnesta, a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera. Bravnesta is indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.
Lantheus Announces FDA Approval for New Drug
Lantheus announced FDA…
Lantheus Reports Q2 Revenue of $388.2M, Announces Merger with Curium
Reports Q2 revenue $388.2M, consensus $363.23M. The company said, "In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus' products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.